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Background: Rituximab has been licensed for the treatment of Rheumatoid Arthritis (RA) for over a decade. We
previously showed that the initial depth of B cell depletion was associated with clinical response; 96% complete versus
74% incomplete depletion at 6 months (p=0.02)[1] and that retreatment of initial non-responders with incomplete
depletion led to 72% response rate in cycle 2 (C2)[2].
Objectives: To validate B cell depletion after the first infusion as a predictor of response to rituximab (Project 1) and
assess outcome of retreatment of first cycle non-responders (Project 2) as a basis for B cell monitoring during rituximab
treatment.
Methods: The published discovery cohorts included 60 patients in Project 1 and 25 patients in Project 2. For this
validation study, we analysed the subsequent consecutive 180 patients with RA treated with rituximab at a single centre.
Each cycle of rituximab consisted of 2x1000mg infusions, repeated on clinical relapse. B cell subsets (naïve, memory and
plasmablast) were measured at baseline, after first infusion of rituximab (2 weeks) and at early B cell repopulation (6
months) using a flow cytometry protocol optimized to detect low numbers of B cell subsets and plasmablasts.  Complete
depletion was defined as total B cell count <0.0001 x 109/L. First cycle non-responders who had incomplete depletion at
C1 were retreated at 6 months.
 
Results: 180 patients (Female=147(81%), median age at rituximab initiation 62(IQR 51-71) years and median disease
duration 10(IQR 5-18) years were studied. 72(40%) patients were biologic-naïve. In C1, 126 (70%) achieved moderate-
good EULAR response. The complete depletion rate for C1 was 54%. Complete depletion was associated with response;
p=0.027 (Table 1).30 patients who were C1 non-responders and had incomplete depletion were retreated at 6 months. Of
these, 20(67%) had complete depletion and 20(67%) responded in C2. Non-responders in C2 had trend to higher
plasmablast numbers at retreatment than responders (p=0.14).
Table 1:B cell depletion and response in validation cohort
Project A
Cohort Depletion Non Response Response p
Validation (n=180) Incomplete 32/82 (39%) 50/82 (61%) 0.036
Complete 23/98 (23%) 75/98 (77%)
Combined Discovery + Validation (n=240) Incomplete 46/117 (39%) 71/117 (61%) 0.003
Complete 26/123(21%) 97/123 (79%)
Conclusions: We have validated that the depth of B cell depletion after the first infusion is a predictor of response to
rituximab in RA. A high degree of response in C2 was also confirmed when C1 non-responders who had incomplete
depletion were retreated.  B cell subsets therefore should be monitored in the routine care of RA patients receiving
rituximab and repeat infusions considered if early depletion is incomplete and clinical response poor.  
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